Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to 121.56%.

  • Enanta Pharmaceuticals' EBITDA Margin rose 828200.0% to 121.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 130.65%, marking a year-over-year increase of 492700.0%. This contributed to the annual value of 130.65% for FY2025, which is 492700.0% up from last year.
  • Enanta Pharmaceuticals' EBITDA Margin amounted to 121.56% in Q3 2025, which was up 828200.0% from 103.16% recorded in Q2 2025.
  • Enanta Pharmaceuticals' EBITDA Margin's 5-year high stood at 103.16% during Q2 2025, with a 5-year trough of 221.7% in Q1 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' median EBITDA Margin value was 156.53% (recorded in 2021), while the average stood at 157.79%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1045300bps in 2021, then surged by 828200bps in 2025.
  • Enanta Pharmaceuticals' EBITDA Margin (Quarter) stood at 109.99% in 2021, then decreased by -16bps to 127.25% in 2022, then plummeted by -52bps to 193.78% in 2023, then rose by 28bps to 138.82% in 2024, then rose by 12bps to 121.56% in 2025.
  • Its last three reported values are 121.56% in Q3 2025, 103.16% for Q2 2025, and 164.32% during Q1 2025.